PL EN


Preferences help
enabled [disable] Abstract
Number of results
2013 | 13 | 2 | 103–108
Article title

Wyzwania terapii otępienia w chorobie Alzheimera

Content
Title variants
EN
Challenges for treatment of dementia in Alzheimer’s disease
Languages of publication
PL
Abstracts
EN
The prevalence of dementia is reaching epidemic proportions globally. Alzheimer’s disease (AD) is one of the main causes of dementia. In the absence of a causal cure for AD, symptomatic treatment play a key role in management the disease. After proper diagnosis of AD patients should be offered the opportunity to benefit from non-pharmacological and pharmacological therapies. Cholinesterase inhibitors (rivastigmine, donepezil, galantamine) and the N-methyl-D-aspartic acid (NMDA) receptor antagonist memantine are currently widely approved for the treatment of AD. These drugs can offer benefits in three main affected areas: activities of daily living, behaviour and cognition. Several guidelines recommend treatment with cholinesterase inhibitors at the time of diagnosis of AD, taking into account expected therapeutic benefits and potential safety issues. These drugs should be used longitudinally with
PL
Rozpowszechnienie choroby Alzheimera (Alzheimer’s disease, AD), która jest najczęstszą przyczyną otępienia, zaczyna osiągać rozmiary światowej epidemii. Kluczowe znaczenie dla pacjenta i jego rodziny ma wczesne, prawidłowe rozpoznanie choroby z możliwością uzyskania szybkiej, profesjonalnej pomocy i optymalnego leczenia farmakologicznego i niefarmakologicznego. Wciąż brakuje skutecznego leczenia przyczynowego, które mogłoby zapobiegać rozwojowi procesu chorobowego lub skutecznie go zahamować. Metody niefarmakologiczne pozwalają opóźnić manifestację kliniczną AD i łagodzić jej przebieg. Z kolei leki zaaprobowane w terapii AD działają objawowo w trzech obszarach: codziennej aktywności życiowej, behawioralnym i poznawczym. W Polsce dysponujemy trzema lekami o potwierdzonej skuteczności klinicznej. Dwa z nich to inhibitory cholinesteraz (rywastygmina, donepezil), trzeci jest antagonistą receptora NMDA (memantyna). Wymienione leki mogą być stosowane w monoterapii lub w terapii łączonej: inhibitor cholinesteraz i memantyna. Leczenie powinno być prowadzone długoterminowo z okresowym monitorowaniem jego efektów. Zasadą kuracji jest nieprzerwane stosowanie maksymalnej, dobrze tolerowanej terapeutycznej dawki dobowej. Oprócz działania usprawniającego funkcje poznawcze leki stosowane w AD wpływają korzystnie na objawy neuropsychiatryczne. Stosowanie innych leków niż inhibitory cholinesteraz i memantyna nie zostało potwierdzone w badaniach klinicznych i nie jest zalecane w rutynowym leczeniu AD.
Discipline
Publisher

Year
Volume
13
Issue
2
Pages
103–108
Physical description
Contributors
  • Zakład Badawczo-Leczniczy Chorób Zwyrodnieniowych CUN, Instytut Medycyny Doświadczalnej i Klinicznej im. M. Mossakowskiego, Polska Akademia Nauk, gabryelewicz@imdik.pan.pl
  • Zakład Badawczo-Leczniczy Chorób Zwyrodnieniowych CUN, Instytut Medycyny Doświadczalnej i Klinicznej im. M. Mossakowskiego, Polska Akademia Nauk
References
  • 1. Ferri C.P., Prince M., Brayne C. i wsp.: Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112–2117.
  • 2. Rocca W.A., Hofman A., Brayne C. i wsp.: Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann. Neurol. 1991; 30: 381–390.
  • 3. Yang S.D., Yu J.S., Liu W.K., Yen S.H.: Synergistic control mechanism for abnormal site phosphorylation of Alzheimer’s diseased brain tau by kinase FA/GSK-3α. Biochem. Biophys. Res. Commun. 1993; 197: 400–406.
  • 4. Vetulani J.: Perspektywy terapii choroby Alzheimera. Psychogeriatria Polska 2004; 1: 253–278.
  • 5. Albert M., DeKosky S., Dickson D. i wsp.: The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7: 270–279.
  • 6. Tapiola T., Alafuzoff I., Herukka S.K. i wsp.: Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 2009; 3: 382–389.
  • 7. Blennow K.: Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx 2004; 1: 213–225.
  • 8. Mayeux R.N.: Clinical practice. Early Alzheimer’s disease. N. Engl. J. Med. 2010; 362: 2194–2201.
  • 9. Burgener S.C., Yang R., Gilbert R., Mars-Yant S.: The effects of a multimodal intervention on outcomes of persons with early-stage dementia. Am. J. Alzheimers Dis. Other Demen. 2008; 23: 382–394.
  • 10. Ruthirakuhan M., Luedke A.C., Tam A. i wsp.: Use of physical and intellectual activities and socialization in the management of cognitive decline of aging and in dementia: a review. J. Aging Res. 2012; 2012: 384875.
  • 11. Scarmeas N., Stern Y., Mayeux R. i wsp.: Mediterranean diet and mild cognitive impairment. Arch. Neurol. 2009; 66: 216–225.
  • 12. Sofi F., Cesari F., Abbate R. i wsp.: Adherence to Mediterranean diet and health status: meta-analysis. BMJ 2008; 337: a1344.
  • 13. Freund-Levy Y., Eriksdotter-Jönhagen M., Cederholm T. i wsp.: ω-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol. 2006; 63: 1402–1408.
  • 14. McKhann G., Drachman D., Folstein M. i wsp.: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–944.
  • 15. Olazarán J., Reisberg B., Clare L. i wsp.: Nonpharmacological therapies in Alzheimer’s disease: a systematic review of efficacy. Dement. Geriatr. Cogn. Disord. 2010; 30: 161–178.
  • 16. Sitzer D.I., Twamley E.W., Jeste D.V.: Cognitive training in Alzheimer’s disease: a meta-analysis of the literature. Acta Psychiatr. Scand. 2006; 114: 75–90.
  • 17. Heese K., Low J.W., Inoue N.: Nerve growth factor, neural stem cells and Alzheimer’s disease. Neurosignals 2006–2007; 15: 1–12.
  • 18. Anand P., Singh B.: A review on cholinesterase inhibitors for Alzheimer’s disease. Arch. Pharm. Res. 2013; 36: 379–399.
  • 19. Hort J., O’Brien J.T., Gainotti G. i wsp.: EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur. J. Neurol. 2010; 17: 1236–1238.
  • 20. Weinstock M.: Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer’s disease. CNS Drugs 1999; 12: 307–323.
  • 21. Corey-Bloom J., Anand R., Veach J.: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int. J. Geriatr. Psychopharmacol. 1998; 1: 55–65.
  • 22. Rösler M., Anand R., Cicin-Sain A. i wsp.: Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318: 633–638.
  • 23. Schneider L.S., Anand R., Farlow M.R.: Systematic review of the efficacy of rivastigmine for patients with Alzheimer’s disease. Int. J. Geriatr. Psychopharmacol. 1998; 1 (supl. 1): S26–S34.
  • 24. Emre M., Aarsland D., Albanese A. i wsp.: Rivastigmine for dementia associated with Parkinson’s disease. N. Engl. J. Med. 2004; 351: 2509–2518.
  • 25. Winblad B., Machado J.C.: Use of rivastigmine transdermal patch in the treatment of Alzheimer’s disease. Expert Opin. Drug Deliv. 2008; 5: 1377–1386.
  • 26. Cummings J., Lefèvre G., Small G., Appel-Dingemanse S.: Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007; 69 (supl. 1): S10–S13.
  • 27. Diniz B.S., Pinto J.A. Jr, Gonzaga M.L. i wsp.: To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer’s disease. Eur. Arch. Psychiatry Clin. Neurosci. 2009; 259: 248–256.
  • 28. Raskind M.A., Peskind E.R., Wessel T., Yuan W.: Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261–2268.
  • 29. Farlow M., Anand R., Messina J. Jr i wsp.: A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur. Neurol. 2000; 44: 236–241.
  • 30. Grossberg G., Sadowsky C., Fröstl H. i wsp.: Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis. Assoc. Disord. 2009; 23: 158–164.
  • 31. Trinh N.H., Hoblyn J., Mohanty S., Yaffe K.: Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease. JAMA 2003; 289: 210–216.
  • 32. Finkel S.I.: Effects on rivastigmine on behavioural and psychological symptoms of dementia in Alzheimer’s disease. Clin. Ther. 2004; 26: 980–990.
  • 33. Schneider L.S., Tariot P.N., Dagerman K.S. i wsp.; CATIE-AD Study Group: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N. Engl. J. Med. 2006; 355: 1525–1538.
  • 34. Ballard C., Hanney M.L., Theudoulou M. i wsp.: The dementia antipsychotic withdrawal trial (DART-AD): long-term follow- up of randomised placebo-controlled trial. Lancet Neurol. 2009; 8: 151–157.
  • 35. Small G.W., Kaufer D., Mendiondo M.S. i wsp.: Cognitive performance in Alzheimer’s disease patients receiving rivastigmine for up to 5 years. Int. J. Clin. Pract. 2005; 59: 473–477.
  • 36. Becker M., Andel R., Rohrer L., Banks S.M.: The effect of cholinesterase inhibitors on risk of nursing home placement among medicaid beneficiaries with dementia. Alzheimer Dis. Assoc. Disord. 2006; 20: 147–152.
  • 37. Waldemar G., Phung K.T., Burns A. i wsp.: Access to diagnostic evaluation and treatment for dementia in Europe. Int. J. Geriatr. Psychiatry 2007; 22: 47–54.
  • 38. Hogan D.B., Goldlist B., Naglie G., Patterson C.: Comparison studies of cholinesterase inhibitors for Alzheimer’s disease. Lancet Neurol. 2004; 3: 622–626.
  • 39. Fitzpatrick A.L., Kuller L.H., Lopez O.L. i wsp.: Survival following dementia onset: Alzheimer’s disease and vascular dementia. J. Neurol. Sci. 2005; 229–230: 43–49.
  • 40. Singh G., Thomas S.K., Arcona S. i wsp.: Treatment persistency with rivastigmine and donepezil in a large state medicaid program. J. Am. Geriatr. Soc. 2005; 53: 1269–1270.
  • 41. Mauskopf J.A., Paramore C., Lee W.C., Snyder E.H.: Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J. Manag. Care Pharm. 2005; 11: 231–239.
  • 42. Winblad B., Engedal K., Soininen H. i wsp.: Long-term efficacy of donepezil in patients with mild to moderate Alzheimer’s disease: results from a one-year placebo controlled study and two-year follow-up study. Int. Psychogeriatr. 2003; 15: 293–294.
  • 43. Sobów T.: Farmakoterapia zaburzeń funkcji poznawczych w AD. W: Diagnostyka i leczenie otępień. Rekomendacje zespołu ekspertów Polskiego Towarzystwa Alzheimerowskiego. Medisfera, Otwock 2012: 85–92.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-7be2b41b-e5b3-413b-afb1-0880906dde73
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.